Literature DB >> 19207959

Hepatitis B and hepatitis C in 2009.

Patrick Marcellin1.   

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are among the most frequent viral infections in humans, and represent a major global public health problem. HBV- and HCV-related chronic hepatitis are the main causes of cirrhosis and hepatocellular carcinoma (HCC) that are responsible for a high rate of morbidity and mortality. End-stage HBV- and HCV-related liver disease and HCC are the main causes of liver transplantation. In the last few years, knowledge of the epidemiology and the natural history of HBV and HCV infection has markedly improved. Furthermore, considerable progress has been made in the efficacy of therapy. New drugs and new therapeutic strategies that are currently under evaluation could further improve the efficacy of therapy in the near future.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19207959     DOI: 10.1111/j.1478-3231.2008.01947.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  33 in total

1.  [Acute loss of vision during therapy of chronic hepatitis C].

Authors:  J P Salgado; R Khoramnia; M M Maier; C P Lohmann; C Winkler von Mohrenfels
Journal:  Ophthalmologe       Date:  2011-06       Impact factor: 1.059

2.  Hepatitis C: The role of new interferons in the era of STAT-C.

Authors:  Rami Moucari; Patrick Marcellin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

3.  ABO blood type, diabetes and risk of gastrointestinal cancer in northern China.

Authors:  Yan Gong; Yun-Sheng Yang; Xiao-Mei Zhang; Ming Su; Jean Wang; Jin-Dong Han; Ming-Zhou Guo
Journal:  World J Gastroenterol       Date:  2012-02-14       Impact factor: 5.742

4.  Frequency of HIV and HCV Co-Infections in Chronic HBV Patients Referred to Taleghani Hospital, Tehran, Iran from 2006 to 2010.

Authors:  Seyed Mohammad Ebrahim Tahaei; Seyed Reza Mohebbi; Pedram Azimzadeh; Mohsen Vahedi; Shohreh Almasi; Sara Romani; Afsaneh Sharifian; Faramarz Derakhshan; Mohammad Reza Zali
Journal:  Hepat Mon       Date:  2011-12-20       Impact factor: 0.660

5.  Impact of ribavirin dose on retreatment of chronic hepatitis C patients.

Authors:  Christiane Stern; Michelle Martinot-Peignoux; Marie Pierre Ripault; Nathalie Boyer; Corinne Castelnau; Dominique Valla; Patrick Marcellin
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

6.  A pilot training program for a motivational enhancement approach to hepatitis C virus treatment among individuals in Israeli methadone treatment centers.

Authors:  Diane S Morse; Miriam Schiff; Shabtay Levit; Rinat Cohen-Moreno; Geoffrey C Williams; Yehuda Neumark
Journal:  Subst Use Misuse       Date:  2012-01       Impact factor: 2.164

7.  Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients.

Authors:  Teerha Piratvisuth; Patrick Marcellin; Matei Popescu; Hans-Peter Kapprell; Vivien Rothe; Zhi-Meng Lu
Journal:  Hepatol Int       Date:  2011-06-24       Impact factor: 6.047

8.  Liver targeted therapies for hepatocellular carcinoma prior to transplant: contemporary management strategies.

Authors:  Mustafa Nazzal; Sameer Gadani; Abdullah Said; Mandy Rice; Obi Okoye; Ahmad Taha; Krista L Lentine
Journal:  Glob Surg       Date:  2018-02-15

9.  Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients.

Authors:  Koffi Alain Attia; Serge Eholié; Eugène Messou; Christine Danel; Sandrine Polneau; Henri Chenal; Thomas Toni; Myreille Mbamy; Catherine Seyler; Naomi Wakasugi; Thérèse N'dri-Yoman; Xavier Anglaret
Journal:  World J Hepatol       Date:  2012-07-27

10.  Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection.

Authors:  Morven Cunningham; Graham R Foster
Journal:  Therap Adv Gastroenterol       Date:  2012-03       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.